Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease
NCT06611111Phase 1Recruiting
- Sponsor
- Upstate Medical University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in post-treatment Lyme disease syndrome (PTLDS) comparing Ceftriaxone with Placebo (2 arms). Primary endpoints: Number of abnormal laboratory measurements, Intensity of Abnormal Laboratory Measurements and 5 more. Started Feb 2025; status: recruiting.
02
Drugs
ceftriaxone
03
Conditions
post-treatment Lyme disease syndrome (PTLDS)
Beyond the preview
Go deeper on NCT06611111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611111.